Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C13H14N2O |
| Molecular Weight | 214.2631 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(CNC1=CC=CC=N1)C2=CC=CC=C2
InChI
InChIKey=ZEAJXCPGHPJVNP-UHFFFAOYSA-N
InChI=1S/C13H14N2O/c16-12(11-6-2-1-3-7-11)10-15-13-8-4-5-9-14-13/h1-9,12,16H,10H2,(H,14,15)
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13999595 |
Primary | Analexin Approved UseAnalgesic, Muscle relaxant Launch Date1959 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
400 mg 2 times / day multiple, oral Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
unhealthy, 70 years |
Disc. AE: Liver injury... AEs leading to discontinuation/dose reduction: Liver injury Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Liver injury | Disc. AE | 400 mg 2 times / day multiple, oral Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
unhealthy, 70 years |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29696
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
||
|
WHO-ATC |
M03BX30
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
||
|
WHO-VATC |
QM03BX30
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C478450
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
PRIMARY | |||
|
209-044-7
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
PRIMARY | |||
|
1204
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
PRIMARY | |||
|
m8702
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
PRIMARY | Merck Index | ||
|
553-69-5
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
PRIMARY | |||
|
9470
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
PRIMARY | |||
|
100000081490
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
PRIMARY | |||
|
FENYRAMIDOL
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
PRIMARY | |||
|
DTXSID00862185
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
PRIMARY | |||
|
2151
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
PRIMARY | |||
|
CHEMBL1697767
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
PRIMARY | |||
|
SUB07602MIG
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
PRIMARY | |||
|
C84054
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
PRIMARY | |||
|
DB13414
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
PRIMARY | |||
|
23634
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
PRIMARY | |||
|
R3V02WL7O3
Created by
admin on Mon Mar 31 19:33:06 GMT 2025 , Edited by admin on Mon Mar 31 19:33:06 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)